Abstract:

Objective  To systematically evaluate the efficacy of gemcitabine monotherapy and gemcitabine combined with nab-paclitaxel in the first-line treatment of advanced metastatic pancreatic cancer in East Asian population， in order to provide a reference for the clinical rational use of gemcitabine in the first-line treatment of patients with metastatic pancreatic cancer in China. Methods According to the preset inclusion and exclusion criteria， literatures published from January 2010 to June 2018 were systematically searched in Wanfang， Cochran Library， MEDLINE， PubMed and CNKI databases. The primary endpoint was objective remission rate （ORR）， and the secondary endpoint was progression-free survival （PFS） and overall survival （OS）. Then the related data was extracted and meta-analysis was performed by using Rev Man 3.5.0 statistical software. Results A total of 38 studies involving 1945 patients were included. The ORR of gemcitabine monotherapy for advanced pancreatic cancer was 0.15 （95％ CI： 0.11-0.18）， the median PFS was 3.39 （95％ CI： 2.74-4.05） months， and the median OS was 7.39 （95％ CI： 6.54-8.23） months. The ORR of gemcitabine combined with nab-paclitaxel in the treatment of advanced pancreatic cancer was 0.40 （95％ CI： 0.29-0.52）， the median PFS was 5.68 （95％ CI： 4.30-7.06） months， and the median OS was 9.80 （95％ CI： 7.89-11.71） months. Conclusion Compared with gemcitabine monotherapy， gemcitabine combined with albumin-bound paclitaxel has obvious superiority and is suitable for East Asian population， especially for patients with advanced pancreatic cancer in China.

Key words:

Metastatic pancreatic adenocarcinoma（mPC）')">"> Metastatic pancreatic adenocarcinoma（mPC）, Gemcitabine, Nab-paclitaxel, Meta-analysis